[go: up one dir, main page]

NO20024610L - Synergistiske metoder og blandinger for behandling av kreft - Google Patents

Synergistiske metoder og blandinger for behandling av kreft

Info

Publication number
NO20024610L
NO20024610L NO20024610A NO20024610A NO20024610L NO 20024610 L NO20024610 L NO 20024610L NO 20024610 A NO20024610 A NO 20024610A NO 20024610 A NO20024610 A NO 20024610A NO 20024610 L NO20024610 L NO 20024610L
Authority
NO
Norway
Prior art keywords
cancer
compositions
treatment
synergistic methods
synergistic
Prior art date
Application number
NO20024610A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024610D0 (no
Inventor
Francis Y Lee
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20024610D0 publication Critical patent/NO20024610D0/no
Publication of NO20024610L publication Critical patent/NO20024610L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20024610A 2000-03-27 2002-09-26 Synergistiske metoder og blandinger for behandling av kreft NO20024610L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19227800P 2000-03-27 2000-03-27
PCT/US2001/009193 WO2001072721A2 (en) 2000-03-27 2001-03-22 Synergistic methods and compositions for treating cancer

Publications (2)

Publication Number Publication Date
NO20024610D0 NO20024610D0 (no) 2002-09-26
NO20024610L true NO20024610L (no) 2002-11-25

Family

ID=22709017

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024610A NO20024610L (no) 2000-03-27 2002-09-26 Synergistiske metoder og blandinger for behandling av kreft

Country Status (24)

Country Link
US (1) US6537988B2 (ru)
EP (1) EP1272193B1 (ru)
JP (1) JP5110756B2 (ru)
KR (1) KR20020084254A (ru)
CN (1) CN100384424C (ru)
AR (1) AR028296A1 (ru)
AT (1) ATE430570T1 (ru)
AU (2) AU2001247683B2 (ru)
BR (1) BR0109517A (ru)
CA (1) CA2404712A1 (ru)
CZ (1) CZ20023220A3 (ru)
DE (1) DE60138611D1 (ru)
ES (1) ES2325055T3 (ru)
HU (1) HUP0301690A3 (ru)
IL (1) IL151373A0 (ru)
MX (1) MXPA02009463A (ru)
MY (1) MY127082A (ru)
NO (1) NO20024610L (ru)
PE (1) PE20011291A1 (ru)
RU (1) RU2264217C2 (ru)
TW (1) TWI310684B (ru)
UY (1) UY26635A1 (ru)
WO (1) WO2001072721A2 (ru)
ZA (1) ZA200207766B (ru)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022461A1 (de) * 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
WO2002028409A2 (en) * 2000-10-05 2002-04-11 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
AU2002214649A1 (en) * 2000-10-16 2002-04-29 Neopharm, Inc. Liposomal formulation of mitoxantrone
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
ES2384789T3 (es) * 2001-03-14 2012-07-12 Bristol-Myers Squibb Company Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas
US20040167134A1 (en) * 2001-05-16 2004-08-26 Christian Bruns Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
DK1441714T3 (da) * 2001-10-25 2008-03-31 Novartis Ag Kombinationer omfattende en selektiv cyclooxygenase-2-inhibitor
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
US7074921B2 (en) * 2001-11-13 2006-07-11 Bristol Myers Squibb Company Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
HRP20040545A2 (en) * 2001-12-20 2005-08-31 Bristol-Myers Squibb Company A Delaware (Usa) Corp Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20030147813A1 (en) * 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
JP4773719B2 (ja) * 2002-05-17 2011-09-14 アベンティス・ファーマ・ソシエテ・アノニム 乳癌および卵巣癌のアジュバント療法におけるドセタキセル／ドキソルビシン／シクロホスファミドの使用
CA2484000A1 (en) * 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
US20050271669A1 (en) * 2002-06-10 2005-12-08 Hohneker John A Combinations comprising epothilones and pharmaceutical uses thereof
RU2379032C9 (ru) * 2002-06-10 2010-03-27 Новартис Аг Комбинации, включающие эпотилоны, и их фармацевтическое применение
NZ538522A (en) * 2002-08-23 2008-03-28 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20040209930A1 (en) * 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060281813A1 (en) * 2003-06-05 2006-12-14 Charles Rubin Methods of treating hyperproliferative cell disorders
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
KR101501870B1 (ko) * 2003-08-27 2015-03-12 옵쏘테크 코포레이션 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법
JP2007510434A (ja) 2003-11-12 2007-04-26 シェーリング　コーポレイション 多重遺伝子発現のためのプラスミドシステム
WO2005046665A1 (en) * 2003-11-13 2005-05-26 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
US7612071B2 (en) * 2004-03-12 2009-11-03 Syntrix Biosystems, Inc. Compositions and methods employing aminopterin
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089496A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
JP2007530517A (ja) * 2004-03-23 2007-11-01 アストラゼネカ アクチボラグ 組合せ療法
DE602005023138D1 (de) * 2004-04-15 2010-10-07 Genencor Int Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
WO2006008639A1 (en) * 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
GB0419071D0 (en) 2004-08-26 2004-09-29 Mgx Internat Ltd Display device
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
ES2356830T3 (es) * 2004-12-03 2011-04-13 Schering Corporation Biomarcadores para preselección de pacientes para terapia de anti-igf-1r.
RU2391982C2 (ru) * 2005-01-19 2010-06-20 Зериа Фармасьютикал Ко., Лтд. Противоопухолевое средство
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
WO2007086879A2 (en) 2005-02-11 2007-08-02 University Of Southern California Method of expressing proteins with disulfide bridges
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
RU2276613C1 (ru) * 2005-03-17 2006-05-20 Российская медицинская академия последипломного образования Министерства здравоохранения Российской Федерации (РМАПО МЗ РФ) Способ лечения злокачественных опухолей головки поджелудочной железы
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
NZ561648A (en) * 2005-04-15 2009-11-27 Schering Corp Methods and composition of IGF1R inhibitors for treating or preventing cancer
EP1877102B1 (en) 2005-04-28 2014-05-07 Danisco US Inc. Tab molecules
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
BRPI0611800A2 (pt) * 2005-06-15 2008-12-09 Schering Corp formulaÇço estÁvel de anticorpo
FR2887454B1 (fr) * 2005-06-28 2009-06-05 Sanofi Aventis Sa Combinaisons antitumorales contenant des derives du taxane et des sigma ligands
WO2007056118A1 (en) 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
CN101415674A (zh) 2006-02-16 2009-04-22 先灵公司 作为erk抑制剂的吡咯烷衍生物
US8044033B2 (en) * 2006-03-02 2011-10-25 The Board Of Regents Of The University Of Texas System Fluorocytidine derivatives and COX-2 inhibitors for the treatment of cancer
WO2007130501A2 (en) * 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
RU2325914C2 (ru) * 2006-06-15 2008-06-10 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ лечения операбельного рака молочной железы
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
US20080085881A1 (en) * 2006-10-06 2008-04-10 Aimery De Gramont Stop-and-go oxaliplatin treatment regimens
WO2008065409A2 (en) * 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
ATE530188T1 (de) * 2007-03-02 2011-11-15 Univ Wollongong Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs
WO2008115478A2 (en) * 2007-03-19 2008-09-25 University Of Medicine And Dentistry Of New Jersey Method of cancer detection and treatment
WO2009035718A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
WO2009033204A1 (en) * 2007-09-12 2009-03-19 University Of Wollongong Multi-component compositions and methods for delivery of anti-cancer agents
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2082745B1 (en) * 2007-12-28 2012-12-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Cancer therapy with a parvovirus combined with chemotherapy
USRE45471E1 (en) * 2008-01-28 2015-04-14 Nanocarrier Co., Ltd. Pharmaceutical composition or combination drug
ES2556353T3 (es) 2008-02-21 2016-01-15 Merck Sharp & Dohme Corp. Compuestos que son inhibidores de las ERK
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20110182888A1 (en) * 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
RU2365370C1 (ru) * 2008-04-29 2009-08-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН Способ лечения рака легкого
EP2915532B1 (en) * 2008-06-17 2016-10-19 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
JP2012508768A (ja) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
KR20170113683A (ko) * 2008-11-28 2017-10-12 노파르티스 아게 피리도〔4,3-ｄ〕피리미딘 유래의 ｈｓｐ90-억제제 및 ｈｅｒ2 억제제를 포함하는 제약 조합물
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
RS53468B (sr) * 2011-03-18 2014-12-31 Metheresis Translational Research Sa Inhibitori met aktivnosti za primenu u cilju povećanja efikasnosti radioterapije
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN103374000B (zh) * 2012-04-13 2015-11-11 中国科学院广州生物医药与健康研究院 嘧啶并二氮杂卓类化合物及其药用组合物和应用
MX2016000364A (es) 2013-07-12 2016-05-09 Ophthotech Corp Metodos para tratar o prevenir afecciones oftalmologicas.
CN107043456B (zh) * 2017-04-19 2019-05-17 川北医学院 对氧环己酮与l-苯丙氨酸氮芥共聚物及其应用
EP3642344B1 (en) 2017-06-21 2024-12-04 The University of North Carolina at Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
AU2019287676A1 (en) 2018-06-13 2021-01-07 The General Hospital Corporation Methods and compositions for chimeric antigen receptor targeting cancer cells
US11068254B1 (en) 2020-06-10 2021-07-20 Cigna Intellectual Property, Inc. Systems and methods for generating and managing domain-based technology architecture
JP2024521216A (ja) * 2021-06-03 2024-05-28 ユニバーシティ・オブ・シンシナティ がんの化学増感剤としてのｂｚｄ－１
CN115814076A (zh) * 2021-07-01 2023-03-21 江苏先声药业有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
US11879010B2 (en) 2021-09-30 2024-01-23 The Charlotte Mecklenburg Hospital Authority Methods and compositions for pretargeted immunotherapy
CN114712377B (zh) * 2022-04-26 2023-08-15 江苏师范大学 断血流皂苷a在制造药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
DE19706584C2 (de) * 1997-02-21 2002-09-26 Aeg Energietechnik Gmbh Hochtemperaturbrennstoffzellen mit Erwärmung des Reaktionsgases
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
AU8382698A (en) * 1997-07-08 1999-02-08 Union Carbide Chemicals & Plastics Technology Corporation Method for reducing sheeting during olefin polymerization
PT1041985E (pt) 1997-12-22 2006-07-31 Schering Corp Combinacao de compostos benzociclo-heptapiridina e farmacos antineoplasicos para tratar doencas proliferativas
RU2230062C2 (ru) * 1999-01-21 2004-06-10 Бристол-Маерс Сквибб Ко. Комплекс ингибитора ras-фарнезилтрансферазы, композиция ингибитора ras-фарнезилтрансферазы, фармацевтическая композиция

Also Published As

Publication number Publication date
DE60138611D1 (de) 2009-06-18
EP1272193A2 (en) 2003-01-08
US20020002162A1 (en) 2002-01-03
MXPA02009463A (es) 2003-04-10
UY26635A1 (es) 2001-10-25
PE20011291A1 (es) 2002-01-13
CN100384424C (zh) 2008-04-30
RU2002129000A (ru) 2004-03-27
BR0109517A (pt) 2006-08-29
NO20024610D0 (no) 2002-09-26
CZ20023220A3 (cs) 2003-11-12
WO2001072721A2 (en) 2001-10-04
AU4768301A (en) 2001-10-08
JP2003528864A (ja) 2003-09-30
HUP0301690A3 (en) 2005-05-30
MY127082A (en) 2006-11-30
JP5110756B2 (ja) 2012-12-26
IL151373A0 (en) 2003-04-10
AR028296A1 (es) 2003-04-30
ZA200207766B (en) 2003-01-20
WO2001072721A3 (en) 2002-06-13
ES2325055T3 (es) 2009-08-25
KR20020084254A (ko) 2002-11-04
ATE430570T1 (de) 2009-05-15
US6537988B2 (en) 2003-03-25
CA2404712A1 (en) 2001-10-04
TWI310684B (en) 2009-06-11
AU2001247683B2 (en) 2006-01-12
RU2264217C2 (ru) 2005-11-20
EP1272193B1 (en) 2009-05-06
CN1419452A (zh) 2003-05-21
HUP0301690A2 (hu) 2003-08-28

Similar Documents

Publication Publication Date Title
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
AU6147401A (en) Compositions and methods for the treatment of cancer
DE60014873D1 (de) Synergistische zusammensetzungen zur krebsbehandlung
IL161775A0 (en) Topical compositions and methods for treatment of adverse effects ofionizing radiation
AU2002226069A1 (en) Compositions comprising temozolomide and thalidomide and methods for the treatment of cancer
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
EE200200673A (et) Kinasoliini derivaadid kasvajate raviks
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
NO20014314D0 (no) Blandinger og metoder for behandling av stafylokokkisk infeksjon
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
FI20011403L (fi) Menetelmä ja koostumukset vatsan sairauksien hoitoon
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
EP1651255A4 (en) TOPICAL VETERINARY COMPOSITIONS AND METHODS OF TREATING AND PREVENTING INFECTIONS
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
IL145397A0 (en) Compositions and methods for treatment of cancer
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
PL368035A1 (en) Compositions and methods for the treatment of cancer
EP1416795A4 (en) COMPOSITIONS AND METHODS OF TREATING DISEASES OF MITOCHONDRIA
NO20010464D0 (no) Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
NO20020369L (no) Sammensetninger for forebyggelse og behandling av nyredysfunksjoner og -sykdommer
NO20031656D0 (no) Kombinasjon omfattende camptothecin og et stillbenderivat for behandling avcancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application